Americas Gastrointestinal Drugs Market Summary
The United States of America gastrointestinal drugs market is projected to grow from 12.3 USD billion in 2024 to 19.7 USD billion by 2035.
Key Market Trends & Highlights
Americas Gastrointestinal Drugs Key Trends and Highlights
- The market is expected to experience a compound annual growth rate of 4.34 percent from 2025 to 2035.
- By 2035, the gastrointestinal drugs market in the United States is anticipated to reach a valuation of 19.7 USD billion.
- In 2024, the market is valued at 12.3 USD billion, indicating a robust growth trajectory.
- Growing adoption of innovative treatment options due to increasing prevalence of gastrointestinal disorders is a major market driver.
Market Size & Forecast
2024 Market Size | 12.3 (USD Billion) |
2035 Market Size | 19.7 (USD Billion) |
CAGR (2025-2035) | 4.34% |
Major Players
AbbVie Inc. (US), AstraZeneca (UK), Valeant (US), Abbott Laboratories (US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals (US), Sanofi (France), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany), Evoke Pharma (US), Valent Pharmaceuticals (US)